ANIX
Anixa Biosciences, Inc.3.5700
+0.3100+9.51%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
117.51MP/E (TTM)
-Basic EPS (TTM)
-0.34Dividend Yield
0%Recent Filings
8-K
10-Q
Q3 FY2025 results
Anixa Biosciences narrowed its operating loss to $2.4M in Q3 FY2025 ended July 31, 2025, a 32% drop from $3.6M a year earlier, while nine-month losses eased 17% to $8.8M from $10.7M, driven by lower R&D outlays on breast cancer vaccines and CAR-T therapies. Cash burn slowed, with operating cash use at $5.9M for the nine months versus $6.4M last year, yielding negative free cash flow of $5.9M since capex details aren't disclosed. Liquidity holds firm at $16.0M in cash and short-term investments, bolstered by $1.9M from an at-the-market offering, enough to fund operations well beyond a year. Expenses fell across segments, yet net loss outpaced operating by $156K due to interest income. Clinical progress shines. Regulatory hurdles could delay vaccine approvals.
10-Q
Q2 FY2025 results
Anixa Biosciences posted a narrower Q2 FY2025 operating loss of $3.0M, down 13% y/y from $3.5M, while YTD loss held at $6.4M, flat y/y, as R&D costs dipped 20% to $1.3M on lower CAR-T spending yet rose in vaccine discovery. Interest income cushioned the net loss to $2.8M, or $0.09 per share on 32.2M diluted shares, matching basic EPS with no anti-dilution. Cash burn eased to $4.4M YTD from $3.8M, leaving $15.6M in cash and equivalents plus short-term investments to fund trials well past a year. CAR-T dosing advances in higher cohorts; breast vaccine nears Phase 1 close. Expenses trimmed via collaborations. Yet clinical setbacks could stall progress.
8-K
Annual meeting outcomes
Anixa Biosciences held its 2025 annual stockholder meeting on March 20, re-electing directors Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr., with strong support averaging over 9.8 million votes for each. Stockholders approved executive compensation on an advisory basis (6.6 million for, 3.4 million against) and ratified Haskell & White LLP as auditors for the fiscal year ending October 31, 2025. They also favored annual advisory votes on pay. Meeting signals board continuity amid biotech uncertainties.
10-Q
Q1 FY2025 results
Anixa Biosciences posted a narrower Q1 FY2025 operating loss of $3.4M, down 6% y/y from $3.6M, while net loss eased to $3.2M from $3.3M, thanks to $173K in interest income offsetting R&D and G&A costs. R&D expenses climbed 15% y/y to $1.6M, driven by higher outside services for the breast cancer vaccine and CAR-T programs, yet G&A dropped 19% y/y to $1.8M on lower investor relations spending. Cash burn stayed controlled at $2.9M for operations, with $17.3M in cash and equivalents plus $16.2M in short-term investments funding runway well beyond 12 months—no debt burdens here. Clinical progress shines: CAR-T trial advances to 4th dose cohort after tolerating 30x initial dose, and breast vaccine data shows immune responses across arms. Expenses narrowed. But clinical trial delays could stretch timelines.
ATOS
Atossa Therapeutics, Inc.
0.72+0.01
BCAX
Bicara Therapeutics Inc.
18.15-0.21
BCTX
BriaCell Therapeutics Corp.
8.70-0.28
ELTX
Elicio Therapeutics, Inc.
8.15-0.37
FATE
Fate Therapeutics, Inc.
1.09-0.03
IBRX
ImmunityBio, Inc.
2.16-0.06
IMMX
Immix Biopharma, Inc.
5.94-0.27
IMNN
Imunon, Inc.
3.88-0.09
LIXT
Lixte Biotechnology Holdings, I
4.10+0.11
MRKR
Marker Therapeutics, Inc.
1.27-0.12